Biosergen publishes interim report for first quarter 2024
Friday, May 31, 2024: Biosergen AB (“Biosergen” or the “Company”) hereby publishes the interim report for the first quarter 2024. The interim report is available as an attached document and on the company website (www.biosergen.net)
Summary of the Interim Report for Q1 2024
| 2024 | 2023 | 2023 | |
| TSEK | Jan-Mar | Jan-Mar | Jan-Dec |
| Profit/loss | |||
| Other income | 693 | 5.315 | 9.378 |
| Profit/loss before depreciation (EBITDA | -6.798 | -5.029 | -27.265 |
| Operating profit/loss before net financials | -6.798 | -5.029 | -27.265 |
| Net financials | -95 | 2 | 228 |
| Netprofit/loss for the period | -6.893 | -5.027 | -27.037 |
| Earnings per share (SEK) | -0,05 | -0,18 | -0,53 |
Highlights during Q1 2024
- March 26, Biosergen announces the outcome in the rights issue.
- March 15, Members of the board of directors and management subscribe in ongoing rights issue
- March 5, Biosergen publishes prospectus due to rights issue of units.
- March 1, Bulletin from the extraordinary general meeting in Biosergen AB (publ).
- February 12, Biosergen receives regulatory approval to test lead candidate BSG005 in patients with invasive fungal infection.
- January 30, Biosergen carries out a rights issue of units of approximately SEK 40.5 million, and secures bridge loan.
- January 12, Biosergen Announces Leadership Transition: Peder M. Andersen to Step Down as CEO, Tine Olesen Appointed as Successor.
HIighlights after the period
- April 16, Conversion of paid subscribed units and first day of trading with warrants of series TO3.
- April 9, Biosergen resolves on a directed issue to underwriters in connection with the completed rights issue.
The Financial report can be found on our website: https://biosergen.net/investors/press-releases